Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AdaptHealth Corp (AHCO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

AdaptHealth CorpTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

AdaptHealth Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? AdaptHealth Corp trades at $5.71 (market cap $753.09M), while Vertex Pharmaceuticals Incorporated trades at $527.97 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 178.3× AdaptHealth Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.

AHCOVRTX
Market Cap
$753.09M$134.25B
Sector
HealthHealth
52-Week High
$13.38$529.65
52-Week Low
$5.22$376.62
Enterprise Value
$2.77B$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AdaptHealth Corp

AdaptHealth (AHCO) trades at $5.63, up 7.85% today but remains under significant pressure after recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal negative profitability with a -6.82% net margin and three consecutive quarterly earnings misses. The company is restructuring by selling its diabetes unit to focus on sleep and respiratory care, but faces multiple securities fraud investigations following guidance revisions.

Despite 75% analyst buy ratings and an $11 consensus price target suggesting 95% upside, substantial risks exist including ongoing legal probes, execution challenges with new fixed-price contracts, and negative cash flow trends. The stock presents high-risk speculation amid operational restructuring and legal uncertainties.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.

Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AdaptHealth Corp

AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.

Read more on AHCO

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX